TP53 and cancer: Limitations of our study include absence of genomic analysis of treated PDXs to determine if acquired TP53 mutations were detected; however, the tumors remained sensitive to re-challenge with combination therapy after re-growth in PDX.008, suggesting that the residual cancer cells were still TP53 WT.